Cargando…

Current Developments in the Use of Biomarkers for Juvenile Idiopathic Arthritis

Use of biomarkers in clinical practice has proved extremely valuable and is a rapidly expanding field. However, despite the huge potential of biomarkers, for juvenile idiopathic arthritis (JIA) there are currently no validated paediatric biomarkers available to help with setting up a more tailored a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duurland, Chantal L., Wedderburn, Lucy R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2014
Materias:	Pediatric Rheumatology (S Ozen, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930839/ https://www.ncbi.nlm.nih.gov/pubmed/24445961 http://dx.doi.org/10.1007/s11926-013-0406-3

Ejemplares similares

Innate Lymphoid Cells and T Cells Contribute to the Interleukin‐17A Signature Detected in the Synovial Fluid of Patients With Juvenile Idiopathic Arthritis
por: Rosser, Elizabeth C., et al.
Publicado: (2019)

Vaccinations in Paediatric Rheumatology: an Update on Current Developments
por: Groot, Noortje, et al.
Publicado: (2015)

JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?
por: Kerrigan, S. A., et al.
Publicado: (2018)

Transitional Care in Rheumatology: a Review of the Literature from the Past 5 Years
por: McDonagh, Janet E., et al.
Publicado: (2019)

Pediatric Antiphospholipid Syndrome: from Pathogenesis to Clinical Management
por: Rosina, Silvia, et al.
Publicado: (2021)

Who Would Have Predicted Multisystem Inflammatory Syndrome in Children?
por: Reiff, Daniel D., et al.
Publicado: (2022)

Correlation of Low CD73 Expression on Synovial Lymphocytes With Reduced Adenosine Generation and Higher Disease Severity in Juvenile Idiopathic Arthritis
por: Botta Gordon‐Smith, Sophie, et al.
Publicado: (2015)

Long‐Term Outcomes Following Achievement of Clinically Inactive Disease in Juvenile Idiopathic Arthritis: The Importance of Definition
por: Shoop‐Worrall, Stephanie J. W., et al.
Publicado: (2018)

Risk Factors and Biomarkers for the Occurrence of Uveitis in Juvenile Idiopathic Arthritis: Data From the Inception Cohort of Newly Diagnosed Patients With Juvenile Idiopathic Arthritis Study
por: Tappeiner, Christoph, et al.
Publicado: (2018)

The Association Between Low Socioeconomic Status With High Physical Limitations and Low Illness Self‐Perception in Patients With Juvenile Idiopathic Arthritis: Results From the Childhood Arthritis Prospective Study,
por: Verstappen, Suzanne M. M., et al.
Publicado: (2015)

Brief Report: The Genetic Profile of Rheumatoid Factor–Positive Polyarticular Juvenile Idiopathic Arthritis Resembles That of Adult Rheumatoid Arthritis
por: Hinks, Anne, et al.
Publicado: (2018)

The Biologic Basis of Clinical Heterogeneity in Juvenile Idiopathic Arthritis
por: Eng, Simon W M, et al.
Publicado: (2014)

Quantifying Temporomandibular Joint Synovitis in Children With Juvenile Idiopathic Arthritis
por: Resnick, Cory M., et al.
Publicado: (2016)

T Cell Expression of Granulocyte–Macrophage Colony-Stimulating Factor in Juvenile Arthritis Is Contingent Upon Th17 Plasticity
por: Piper, Christopher, et al.
Publicado: (2014)

Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives
por: Ambler, William G., et al.
Publicado: (2022)

Distinct Effects of Methotrexate and Etanercept on the B Cell Compartment in Patients With Juvenile Idiopathic Arthritis
por: Glaesener, Stephanie, et al.
Publicado: (2014)

Juvenile Idiopathic Arthritis in the Era of International Cooperation
por: Uziel, Yosef
Publicado: (2017)

Development and External Validation of a Model Predicting New‐Onset Chronic Uveitis at Different Disease Durations in Juvenile Idiopathic Arthritis
por: van Straalen, Joeri W., et al.
Publicado: (2022)

Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate
por: Lovell, Daniel J, et al.
Publicado: (2020)

Identification of Novel Loci Shared by Juvenile Idiopathic Arthritis Subtypes Through Integrative Genetic Analysis
por: Li, Jin, et al.
Publicado: (2022)

Long‐Term Safety, Efficacy, and Quality of Life in Patients With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept for Up to Seven Years
por: Lovell, Daniel J., et al.
Publicado: (2015)

Microbiome Analytics of the Gut Microbiota in Patients With Juvenile Idiopathic Arthritis: A Longitudinal Observational Cohort Study
por: van Dijkhuizen, E. H. Pieter, et al.
Publicado: (2019)

Efficacy and Safety of Tocilizumab for Polyarticular‐Course Juvenile Idiopathic Arthritis in the Open‐Label Two‐Year Extension of a Phase III Trial
por: Brunner, Hermine I., et al.
Publicado: (2021)

Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling
por: Deakin, Claire T., et al.
Publicado: (2018)

Comparison of Children With Onset of Juvenile Dermatomyositis Symptoms Before or After Their Fifth Birthday in a UK and Ireland Juvenile Dermatomyositis Cohort Study
por: Martin, N, et al.
Publicado: (2012)

Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans
por: Kimura, Yukiko, et al.
Publicado: (2021)

Whole Blood Gene Expression Profiling Predicts Therapeutic Response at Six Months in Patients With Polyarticular Juvenile Idiopathic Arthritis
por: Jiang, Kaiyu, et al.
Publicado: (2014)

Platelet Glycoprotein Ib α‐Chain as a Putative Therapeutic Target for Juvenile Idiopathic Arthritis: A Mendelian Randomization Study
por: Luo, Shan, et al.
Publicado: (2021)

Impact of Antiinflammatory Treatment on the Onset of Uveitis in Juvenile Idiopathic Arthritis: Longitudinal Analysis From a Nationwide Pediatric Rheumatology Database
por: Tappeiner, Christoph, et al.
Publicado: (2015)

Subcutaneous Abatacept in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: Results From a Phase III Open‐Label Study
por: Brunner, Hermine I., et al.
Publicado: (2018)

Anti–Cytosolic 5′‐Nucleotidase 1A Autoantibodies Are Absent in Juvenile Dermatomyositis
por: Rietveld, Anke, et al.
Publicado: (2021)

Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study
por: Davies, Rebecca, et al.
Publicado: (2015)

High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti–Tumor Necrosis Factor Therapy
por: Mor‐Vaknin, Nirit, et al.
Publicado: (2018)

Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open‐Label, Randomized Study
por: Quartier, Pierre, et al.
Publicado: (2020)

Treatment to Target Using Recombinant Interleukin‐1 Receptor Antagonist as First‐Line Monotherapy in New‐Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five‐Year Follow‐Up Study
por: ter Haar, Nienke M., et al.
Publicado: (2019)

Galectin‐9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation
por: Wienke, Judith, et al.
Publicado: (2019)

Patterns of clinical joint inflammation in juvenile idiopathic arthritis
por: Heckert, Sascha L, et al.
Publicado: (2023)

Genomic risk scores for juvenile idiopathic arthritis and its subtypes
por: Cánovas, Rodrigo, et al.
Publicado: (2020)

Comparison of the Utility and Validity of Three Scoring Tools to Measure Skin Involvement in Patients With Juvenile Dermatomyositis
por: Campanilho‐Marques, Raquel, et al.
Publicado: (2016)

Advances in the treatment of polyarticular juvenile idiopathic arthritis
por: Webb, Kate, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_sac2m1bagtavg29e7hna75tbcj